Global Single-use Bioprocessing System Market 2017-2021
About Single-Use Bioprocessing System
The single-use bioprocessing systems market is rapidly evolving. It focuses on developing disposable bioprocessing equipment and accessories for manufacturing of biopharmaceutical products. Bioprocess is a technique that produces biological materials such as a genetically engineered microbial strain for commercial use. For example, commercially useful chemicals are produced through bioprocess techniques such as microbial fermentation or degradation. The traditional approaches in bioprocessing involve stainless steel equipment that are not just difficult to maintain but also time-consuming and costly.
Technavio’s analysts forecast the global single-use bioprocessing system market to grow at a CAGR of 7.83% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global single-use bioprocessing system market for 2017-2021. To calculate the market size, the report considers the revenue generated from retail sales of key vendors to end-users such as pharmaceutical companies, CROs/CMOs, biotech companies, and academic and research institutions.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Single-Use Bioprocessing System Market 2017-2021
Technavio recognizes the following companies as the key players in the global single-use bioprocessing system market: Danaher, GE Healthcare, Merck, Sartorius, and Thermo Fisher Scientific.
Other Prominent Vendors in the market are: Broadley-James Corporation, Eppendorf, and Saint-Gobain.
Commenting on the report, an analyst from Technavio’s team said: “One trend in market is increasing adoption of single-use bioprocessing in pre-clinical and commercial stage. Single-use bioprocess systems have currently established themselves as the accepted choice at both the pre-clinical and bioproduction stage. Biopharmaceutical companies are increasingly accepting these systems as a trusted alternative at the commercial stage to accelerate the production process.”
According to the report, one driver in market is SUT combats global drug shortage problem. The biopharmaceutical industry is shifting toward SUTs to combat the global drug shortage. Companies struggle to meet clinical trial timelines and invariably suffer losses, which could be avoided. The growing evidence of sterility, along with regulatory organizations encouraging pharma companies to switch to single-use technologies, hints toward a transition. Companies that have integrated and shifted toward a single-use system have expressed their satisfaction in terms of lower costs, reduced overall contamination rates, and enhanced production throughput efficiency. While using SUTs, companies spend lesser time with disassembly and clean-up of the system, resulting in a quicker turnaround time for new batches of medications. SUT allows for continuous manufacturing and saves the companies production time. This translates to huge cost savings, which the pharma companies can use in other aspects of drug development. Thus, single-use technology is the most cost-efficient solution to increase rapidity in drug development, support larger batches of production, and achieve a quicker time to market the solutions.
Further, the report states that one challenges in market is lack of standardization across suppliers. The absence of standardization in equipment is a key challenge for end-users in the single-use bioprocessing systems market, despite the advantages of cost and faster implementation. Generally, components sourced from one supplier cannot be used with components from another due to lack of compatibility and different materials used by suppliers to manufacture the same equipment. This is forcing vendors to stick to one supplier or purchase duplicate versions of same components, which is increasing their inventory management costs. Some suppliers have stated the reasons for the absence of standardization, which is because vendors are customizing equipment according to their respective needs, which leads to additional charge from the supplier's side. For example, a customized assembly would cost more in comparison to off-the-shelf assembly when solutions have to be adjusted to a certain manufacturing site.
Danaher, GE Healthcare, Merck, Sartorius, Thermo Fisher Scientific, Broadley-James Corporation, Eppendorf, and Saint-Gobain.